Clinical Trial

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-04-01; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2025-04-25
Trial Details
NCT Number NCT06906341
Lead Sponsor Corcept Therapeutics
Conditions Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Enrollment 270 participants
Start Date 2025-04-11
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-16